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Table 1. Amino acid sequences of the V3 region of HIV and antibody titers of HIV-infected subjects in Bangkok.
Antibody titers by (ELISA)
Patient
no.
I
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II
12
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17
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19
20
21
Amino acid sequence Thai A Thai B HGP-30 Route of infection
CTRPSNNTRTSITIGPGQVFYRTGDIIGDIRKAYC >6400 <200 200 Heterosexual intercourse
-----------------------------------
1600 800 800 Heterosexual intercourse
-----------------------------------
>6400 <200 200 Drug injection
-----------------------------------
6400 400 <200 Heterosexual intercourse
------------P---------------------- >6400 400 1600 Heterosexual intercourse
------------------A----------------- 6400 800 1600 Heterosexual intercourse
------------P-----A---------------- >6400 >6400 800 Heterosexual intercourse
------------P-----A---------------- 6400 1600 200 Heterosexual intercourse
---------------------A----E-------- 6400 3200 3200 Heterosexual intercourse
-----------L------A-------T-------- 6400 3200 800 Heterosexual intercourse
-----------V------A-------T-N------ 6400 200 200 Drug injection
-------------M----A-V-----T-N------ 200 400 <200 Homosexual intercourse
-----------LP-----A-------T-------- 6400 400 400 Drug injection
-------M------------V-------N------ 6400 800 200 Heterosexual intercourse
----------Q-M-------V-----T-------- 3200 200 1600 Heterosexual intercourse
CTRPNNNTRKSIHLGPGQAWYTTGQIIGDIRQAHC 800 3200 800 Heterosexual intercourse
-----------------------------------
3200 6400 400 Heterosexual intercourse
-----------------------------------
1600 3200 800 Heterosexual intercourse
-----------------------------------
3200 >6400 1600 Heterosexual intercourse
------------------V-F----D--------- 1600 3200 800 Heterosexual intercourse
----------G---------V----R--------- 800 3200 800 Heterosexual intercourse
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Control of a Hepatitis A Outbreak by Active
Immunization of High-Risk Susceptible Subjects
Colleagues-Hepatitis A is an enterically transmitted disease
whose prevalence is related to economic development. In Thai-
land, which is rapidly developing into an industrialized nation.
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there has been a rapid decline in anti-hepatitis A virus (HAV)
seroprevalence among persons <20 years old. rendering a sub-
stantial percentage susceptible to disease [1, 2]. This has re-
sulted in numerous recent outbreaks of hepatitis A among
young Thai adults. Control of such outbreaks has previously
depended on the use of immune globulin. which provides only
short-term protection and no public health benefit. Therefore,
we investigated the feasibility of actively vaccinating seronega-
tive susceptible subjects as a means to control hepatitis A. The
vaccine selected for use was a novel "virosorne" formulation
that has previously been found to elicit rapid seroconversion
(97%-100% by 14 days after immunization) after a single
dose [3].
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An outbreak of hepatitis A occurred among a class of 61 radi-
ology students at Chulalongkorn Hospital. The index case be-
came infected after exposure as part of her clinical duties to a
child with acute disease. About 2 weeks later, two classmates
presented with fever, anorexia, and jaundice. Both were diag-
nosed as having hepatitis A by a positive anti-HAY IgM anti-
body test (Abbott Laboratories, Abbott Park, IL). The remain-
ing students were immediately tested for anti-HAY antibodies
with 26 (13 male, 13 female; mean age, 19.5 years) found to be
seronegative and therefore susceptible.
All 26 subjects received a single intramuscular dose of vac-
cine. Mild, transient local reactions, characterized by tenderness
at the injection site, were reported by 42%of the vaccinees. The
immune response was measured by an IgG-specific ELISA [3].
All subjects were seropositive (~20 mlU/mL) at I and 6 months
after vaccination, with geometric mean titers of 432 and 463
mlU/mL, respectively. There was no clinical evidence ofactive
hepatitis A in this group. Liver function test results remained
within normal ranges over the 6-month observation period.
Therefore, the use of a hepatitis A vaccine in high-risk subjects
appeared to be effective at preventing disease spread.
Hepatitis A vaccines have recently become commercially
Hepatitis E Virus and Posttransfusion Hepatitis
Colleagues-Since the cloning of hepatitis E virus (HEY) and
the development of an ELISA [1], many seroepidemiologic stud-
ies have been reported [2-4]. Recent studies of human volun-
teer and animal experiments have revealed viremic status [5,6].
Therefore, the possibility of transfusion-related HEY infection
has been considered [5]. In a prospective study of posttransfu-
sion hepatitis (PTH) in Taiwan, we have encountered 6 patients
with non-A, non-B, non-C hepatitis [7]. Accordingly, we used
the HEY nested polymerase chain reaction (PCR) and an
ELISA to study the role of HEY in these patients.
Six patients developed PTH in a prospective study [7]. They
received blood or blood components from donors negative for
hepatitis B virus (HBY) surface antigen and with serum alanine
aminotransferase (ALT) <45 lUlL [7]. They were negative by
serology for IgM antibodies to the following: hepatitis A virus,
HBY core antigen, cytomegalovirus, Epstein-Barr virus, hepati-
tis C virus (HCY), and hepatitis D virus. Sera were also negative
for HBY DNA and HCY RNA by PCR [7]. Subjects were na-
tives of Taiwan and had no history of traveling abroad prior to
disease onset. There were 4 men and 2 women with mean age of
42 years (range, 20-68), mean peak ALT of 286 lUlL (range,
102-537), and mean incubation period of 63 days (range, 15-
126). All patients recovered within 3 months, and none had
evidence of chronicity in 3-5 years of follow-up. Serial serum
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available in several countries. On the basis of these promising
results, their use, either alone or in combination with immune
globulin, should be considered as a means to control outbreaks
or epidemics of hepatitis A.
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samples of these 6 patients were tested in duplicate for HEY
antibodies by ELISA (Diagnostic Biotechnology; Singapore) [3]
and for HEY RNA by PCR. RNA from 100 JLL of serum was
extracted [7], reverse-transcribed into eDNA, and amplified by
nested PCR using primers as previously described [8].
All 6 patients were negative for HEY RNA by PCR. By
ELISA, all the pretransfusion samples were negative. However,
positive results were found in 2 sera ofa patient (6 and 9 months
after transfusion) and in 3 sera of another patient (3, 4, and 8
months after transfusion). The cutoff values of these 5 samples
were between 1.8 and 3.4. The other serial specimens were nega-
tive.
Transmission of HEY has been documented by the fecal-oral
route [8]. Although the possibility of HEY infection resulting
from transfusion of HEY-containing blood has been raised,
screening of ALT should reduce the possibility, as HEY viremia
appears only at the acute stage of infection [5, 6]. Therefore, it
was reasonable that none of our patients were infected with
HEY. This might be another reason for ALT screening after
antibodies to HCY have appeared. It is now well known that
anti-HEY IgG is long-lasting once it appears [2, 5, 6]. In the 5
seropositive samples, because of the negative PCR results and
because the appearance of HEY antibody was not consistent,
these results were considered to be falsely positive. Therefore,
the interpretation of current HEY ELISA results should be
cautious as to clinical and seroepidemiologic diagnosis until
confirmatory tests are available.
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